Long-term control of peritoneal metastases following claudin 18.2-targeted CAR T-Cell therapy in advanced gastric cancer
- Study type
- Other
- Study name
- Satri-cel (CLDN18.2 CAR T)
- Design
- Case series of three patients enrolled in a phase 1 trial
- Sample size
- 3 patients
- Source
- J Hematol Oncol · 2026
- Trial registration
- NCT03874897
In plain words
Stomach cancer that has spread to the lining of the abdomen (the peritoneum) has few treatment options. In this report, three patients were treated with a type of cell therapy (CAR T) that targets a protein called claudin 18.2 on cancer cells; all three benefited, and the disease in the abdominal lining was controlled for a long time. Two patients lived for 44 and 35 months, and one patient achieved long-term control after surgery. This report includes only three patients and is not enough to judge how well this treatment works overall.
Key results
Treatment arms and regimens
Three patients were treated with claudin 18.2-targeted CAR T cells (satri-cel). Dose details in the full text.
Source of the regimen details: ClinicalTrials.gov NCT03874897 (dose not stated in the abstract; details in the full text)
Doses are given for the information of specialists, as in this study’s protocol, and are not a prescription. Every drug must be prescribed by the treating physician for the individual patient.
Study population
Three patients with gastric cancer and peritoneal metastases enrolled in the phase 1 trial of satri-cel. All three had high CLDN18.2 (claudin 18.2) expression.
Endpoints
No formal primary or secondary endpoint is defined in the abstract. Reported outcomes include clinical and radiological benefit, durable control of peritoneal disease, overall survival, and persistence and infiltration of CAR T cells in peripheral blood and tumour tissue.
Safety and side effects
No adverse event information is reported in the abstract; refer to the full text for this section.
Clinical significance and place in guidelines
This small report (three patients) is hypothesis-generating and supports durable activity of CLDN18.2-targeted CAR T therapy in gastric cancer with peritoneal metastases. The abstract provides no evidence of a change in practice or guideline endorsement; the availability and place of this therapy should be checked in current sources and guidelines.
Limitations
The very small number of patients (3), the descriptive nature of the report, the lack of a control group, and the absence of safety and dose information in the abstract are the main limitations. Patients were selected for high CLDN18.2 expression, so generalisability to all patients is limited.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.